SweetSpot announces initiative to monitor blood glucose levels in veterans with diabetes

SweetSpot Diabetes Care, Inc. today announced an initiative to remotely monitor blood glucose levels in veterans with diabetes, which will be funded by an award from The U.S. Department of Veteran Affair's industry innovation competition known as VAi2. Aimed at improving care and reducing complications in patients with diabetes, the SweetSpot initiative will begin with a trial in Dayton, OH.

With SweetSpot, veterans with diabetes can stay at home and send data from their blood glucose testing devices to VistA - the VA's electronic medical record system. Health care providers can monitor this data and will be alerted when readings indicate a patient may be headed for complications that arise when glucose levels are poorly controlled.  SweetSpot's presentation of a patient's blood glucose data can also help a patient get care in a local setting with support from a specialist – lowering the cost of care while preserving the quality and improving convenience for the veteran.

"Our mission is to improve the lives of patients with diabetes and we are especially eager to do so for veterans," said Christopher Logan, chief executive officer of SweetSpot, "The VA is a leader in using information technology to improve health care while looking for efficiencies. We are excited to be working with them and look forward to serving the nearly one million veterans with diabetes."

"Cloud Computing holds tremendous promise for a huge, distributed medical system like the VA," said Adam Greene, SweetSpot Founder and Chief Technology Officer, "We look forward to being one of the first cloud technologies to be certified to operate by the VA."  

Source:

SweetSpot Diabetes Care, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Microplastics detected in human blood linked to altered coagulation markers